nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.152	1	CbGbCtD
Ziprasidone—Pneumonia aspiration—Riluzole—amyotrophic lateral sclerosis	0.0153	0.0289	CcSEcCtD
Ziprasidone—HTR2A—phrenic nerve—amyotrophic lateral sclerosis	0.0151	0.0643	CbGeAlD
Ziprasidone—Faecaloma—Riluzole—amyotrophic lateral sclerosis	0.0117	0.0221	CcSEcCtD
Ziprasidone—Faecalith—Riluzole—amyotrophic lateral sclerosis	0.0117	0.0221	CcSEcCtD
Ziprasidone—Circumoral paresthesia—Riluzole—amyotrophic lateral sclerosis	0.0102	0.0194	CcSEcCtD
Ziprasidone—Trismus—Riluzole—amyotrophic lateral sclerosis	0.01	0.0189	CcSEcCtD
Ziprasidone—HTR3A—cranial nerve—amyotrophic lateral sclerosis	0.00972	0.0415	CbGeAlD
Ziprasidone—Uterine haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00955	0.0181	CcSEcCtD
Ziprasidone—Hypochromic anaemia—Riluzole—amyotrophic lateral sclerosis	0.00861	0.0163	CcSEcCtD
Ziprasidone—HTR1B—cranial nerve—amyotrophic lateral sclerosis	0.00816	0.0348	CbGeAlD
Ziprasidone—VIIth nerve paralysis—Riluzole—amyotrophic lateral sclerosis	0.00813	0.0154	CcSEcCtD
Ziprasidone—Fungal skin infection—Riluzole—amyotrophic lateral sclerosis	0.00799	0.0151	CcSEcCtD
Ziprasidone—HTR1D—cranial nerve—amyotrophic lateral sclerosis	0.0079	0.0337	CbGeAlD
Ziprasidone—Furunculosis—Riluzole—amyotrophic lateral sclerosis	0.00785	0.0148	CcSEcCtD
Ziprasidone—Personality disorder—Riluzole—amyotrophic lateral sclerosis	0.00772	0.0146	CcSEcCtD
Ziprasidone—Paraesthesia oral—Riluzole—amyotrophic lateral sclerosis	0.00712	0.0134	CcSEcCtD
Ziprasidone—Priapism—Riluzole—amyotrophic lateral sclerosis	0.0069	0.013	CcSEcCtD
Ziprasidone—Furuncle—Riluzole—amyotrophic lateral sclerosis	0.0068	0.0129	CcSEcCtD
Ziprasidone—Muscle relaxant therapy—Riluzole—amyotrophic lateral sclerosis	0.00671	0.0127	CcSEcCtD
Ziprasidone—Bundle branch block—Riluzole—amyotrophic lateral sclerosis	0.00661	0.0125	CcSEcCtD
Ziprasidone—Hypotonia—Riluzole—amyotrophic lateral sclerosis	0.00635	0.012	CcSEcCtD
Ziprasidone—HTR7—cranial nerve—amyotrophic lateral sclerosis	0.00629	0.0269	CbGeAlD
Ziprasidone—HTR7—pons—amyotrophic lateral sclerosis	0.00622	0.0265	CbGeAlD
Ziprasidone—Hostility—Riluzole—amyotrophic lateral sclerosis	0.00603	0.0114	CcSEcCtD
Ziprasidone—Hypothermia—Riluzole—amyotrophic lateral sclerosis	0.00595	0.0113	CcSEcCtD
Ziprasidone—Body temperature decreased—Riluzole—amyotrophic lateral sclerosis	0.00595	0.0113	CcSEcCtD
Ziprasidone—Suicide attempt—Riluzole—amyotrophic lateral sclerosis	0.00588	0.0111	CcSEcCtD
Ziprasidone—Gingival bleeding—Riluzole—amyotrophic lateral sclerosis	0.00588	0.0111	CcSEcCtD
Ziprasidone—Completed suicide—Riluzole—amyotrophic lateral sclerosis	0.00568	0.0107	CcSEcCtD
Ziprasidone—Myoclonus—Riluzole—amyotrophic lateral sclerosis	0.00555	0.0105	CcSEcCtD
Ziprasidone—Blepharitis—Riluzole—amyotrophic lateral sclerosis	0.00542	0.0103	CcSEcCtD
Ziprasidone—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.00531	0.01	CcSEcCtD
Ziprasidone—DRD1—nerve—amyotrophic lateral sclerosis	0.00516	0.022	CbGeAlD
Ziprasidone—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.00514	0.00972	CcSEcCtD
Ziprasidone—HTR3A—nerve—amyotrophic lateral sclerosis	0.00498	0.0213	CbGeAlD
Ziprasidone—Hypokinesia—Riluzole—amyotrophic lateral sclerosis	0.00494	0.00934	CcSEcCtD
Ziprasidone—Blood creatine phosphokinase increased—Riluzole—amyotrophic lateral sclerosis	0.00485	0.00916	CcSEcCtD
Ziprasidone—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.0048	0.00908	CcSEcCtD
Ziprasidone—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.00467	0.00883	CcSEcCtD
Ziprasidone—Flat affect—Riluzole—amyotrophic lateral sclerosis	0.00463	0.00875	CcSEcCtD
Ziprasidone—Mania—Riluzole—amyotrophic lateral sclerosis	0.00459	0.00867	CcSEcCtD
Ziprasidone—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.00451	0.00852	CcSEcCtD
Ziprasidone—Extrapyramidal disorder—Riluzole—amyotrophic lateral sclerosis	0.00443	0.00838	CcSEcCtD
Ziprasidone—Amblyopia—Riluzole—amyotrophic lateral sclerosis	0.00432	0.00817	CcSEcCtD
Ziprasidone—HTR7—peripheral nervous system—amyotrophic lateral sclerosis	0.00414	0.0177	CbGeAlD
Ziprasidone—Glycosuria—Riluzole—amyotrophic lateral sclerosis	0.00412	0.00778	CcSEcCtD
Ziprasidone—Gamma-glutamyltransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00406	0.00767	CcSEcCtD
Ziprasidone—HTR2A—cranial nerve—amyotrophic lateral sclerosis	0.00392	0.0167	CbGeAlD
Ziprasidone—Delirium—Riluzole—amyotrophic lateral sclerosis	0.00388	0.00733	CcSEcCtD
Ziprasidone—HTR2A—pons—amyotrophic lateral sclerosis	0.00388	0.0165	CbGeAlD
Ziprasidone—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.0038	0.00718	CcSEcCtD
Ziprasidone—HTR1E—brainstem—amyotrophic lateral sclerosis	0.00379	0.0162	CbGeAlD
Ziprasidone—Accidental injury—Riluzole—amyotrophic lateral sclerosis	0.00377	0.00713	CcSEcCtD
Ziprasidone—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.00372	0.00703	CcSEcCtD
Ziprasidone—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.00367	0.00694	CcSEcCtD
Ziprasidone—Cough increased—Riluzole—amyotrophic lateral sclerosis	0.00365	0.00689	CcSEcCtD
Ziprasidone—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.0036	0.0068	CcSEcCtD
Ziprasidone—Gout—Riluzole—amyotrophic lateral sclerosis	0.00357	0.00675	CcSEcCtD
Ziprasidone—Leukocytosis—Riluzole—amyotrophic lateral sclerosis	0.00355	0.00671	CcSEcCtD
Ziprasidone—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.00353	0.00667	CcSEcCtD
Ziprasidone—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.00353	0.00667	CcSEcCtD
Ziprasidone—Cataract—Riluzole—amyotrophic lateral sclerosis	0.00351	0.00663	CcSEcCtD
Ziprasidone—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.00342	0.00646	CcSEcCtD
Ziprasidone—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.0034	0.00642	CcSEcCtD
Ziprasidone—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.00334	0.00631	CcSEcCtD
Ziprasidone—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.00334	0.00631	CcSEcCtD
Ziprasidone—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.00334	0.00631	CcSEcCtD
Ziprasidone—HTR2A—hindlimb—amyotrophic lateral sclerosis	0.00331	0.0141	CbGeAlD
Ziprasidone—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.0033	0.00623	CcSEcCtD
Ziprasidone—Melaena—Riluzole—amyotrophic lateral sclerosis	0.00326	0.00616	CcSEcCtD
Ziprasidone—HTR7—nerve—amyotrophic lateral sclerosis	0.00322	0.0138	CbGeAlD
Ziprasidone—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00322	0.00609	CcSEcCtD
Ziprasidone—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.00313	0.00592	CcSEcCtD
Ziprasidone—DRD2—nerve—amyotrophic lateral sclerosis	0.00305	0.013	CbGeAlD
Ziprasidone—ADRA2A—peripheral nervous system—amyotrophic lateral sclerosis	0.00303	0.0129	CbGeAlD
Ziprasidone—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00302	0.0057	CcSEcCtD
Ziprasidone—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00302	0.0057	CcSEcCtD
Ziprasidone—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.00293	0.00553	CcSEcCtD
Ziprasidone—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.0029	0.00547	CcSEcCtD
Ziprasidone—SLC6A4—hindbrain—amyotrophic lateral sclerosis	0.00285	0.0121	CbGeAlD
Ziprasidone—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.00284	0.00537	CcSEcCtD
Ziprasidone—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00284	0.00537	CcSEcCtD
Ziprasidone—HTR2A—appendage—amyotrophic lateral sclerosis	0.00284	0.0121	CbGeAlD
Ziprasidone—Phlebitis—Riluzole—amyotrophic lateral sclerosis	0.00281	0.00531	CcSEcCtD
Ziprasidone—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00278	0.00526	CcSEcCtD
Ziprasidone—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00278	0.00526	CcSEcCtD
Ziprasidone—Eczema—Riluzole—amyotrophic lateral sclerosis	0.0027	0.00509	CcSEcCtD
Ziprasidone—Injury—Riluzole—amyotrophic lateral sclerosis	0.00264	0.00498	CcSEcCtD
Ziprasidone—HTR2A—peripheral nervous system—amyotrophic lateral sclerosis	0.00258	0.011	CbGeAlD
Ziprasidone—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.00258	0.00487	CcSEcCtD
Ziprasidone—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00258	0.00487	CcSEcCtD
Ziprasidone—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.00257	0.00485	CcSEcCtD
Ziprasidone—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00256	0.00483	CcSEcCtD
Ziprasidone—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00255	0.00481	CcSEcCtD
Ziprasidone—HTR1A—hindbrain—amyotrophic lateral sclerosis	0.00253	0.0108	CbGeAlD
Ziprasidone—H1F0—embryo—amyotrophic lateral sclerosis	0.00245	0.0104	CbGeAlD
Ziprasidone—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00243	0.0046	CcSEcCtD
Ziprasidone—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.00242	0.00458	CcSEcCtD
Ziprasidone—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00242	0.00458	CcSEcCtD
Ziprasidone—HTR7—hindbrain—amyotrophic lateral sclerosis	0.00241	0.0103	CbGeAlD
Ziprasidone—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.00237	0.00447	CcSEcCtD
Ziprasidone—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00234	0.00442	CcSEcCtD
Ziprasidone—ADRA1A—hindbrain—amyotrophic lateral sclerosis	0.00233	0.00994	CbGeAlD
Ziprasidone—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.0023	0.00435	CcSEcCtD
Ziprasidone—DRD2—hindbrain—amyotrophic lateral sclerosis	0.00228	0.00975	CbGeAlD
Ziprasidone—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.00228	0.0043	CcSEcCtD
Ziprasidone—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00225	0.00426	CcSEcCtD
Ziprasidone—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00224	0.00423	CcSEcCtD
Ziprasidone—DRD1—brainstem—amyotrophic lateral sclerosis	0.00221	0.00945	CbGeAlD
Ziprasidone—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00221	0.00418	CcSEcCtD
Ziprasidone—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.0022	0.00417	CcSEcCtD
Ziprasidone—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00219	0.00414	CcSEcCtD
Ziprasidone—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00405	CcSEcCtD
Ziprasidone—HTR3A—brainstem—amyotrophic lateral sclerosis	0.00214	0.00913	CbGeAlD
Ziprasidone—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00209	0.00396	CcSEcCtD
Ziprasidone—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00209	0.00396	CcSEcCtD
Ziprasidone—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00204	0.00385	CcSEcCtD
Ziprasidone—HTR2A—nerve—amyotrophic lateral sclerosis	0.00201	0.00858	CbGeAlD
Ziprasidone—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00201	0.00379	CcSEcCtD
Ziprasidone—HTR1E—nervous system—amyotrophic lateral sclerosis	0.00199	0.00849	CbGeAlD
Ziprasidone—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00196	0.0037	CcSEcCtD
Ziprasidone—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00193	0.00364	CcSEcCtD
Ziprasidone—HTR1E—central nervous system—amyotrophic lateral sclerosis	0.00191	0.00817	CbGeAlD
Ziprasidone—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00191	0.00361	CcSEcCtD
Ziprasidone—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00191	0.0036	CcSEcCtD
Ziprasidone—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00189	0.00358	CcSEcCtD
Ziprasidone—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00188	0.00355	CcSEcCtD
Ziprasidone—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00187	0.00353	CcSEcCtD
Ziprasidone—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00187	0.00353	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00183	0.00346	CcSEcCtD
Ziprasidone—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00182	0.00344	CcSEcCtD
Ziprasidone—HTR1B—brainstem—amyotrophic lateral sclerosis	0.00179	0.00766	CbGeAlD
Ziprasidone—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00179	0.00338	CcSEcCtD
Ziprasidone—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00336	CcSEcCtD
Ziprasidone—DRD4—brain—amyotrophic lateral sclerosis	0.00176	0.00752	CbGeAlD
Ziprasidone—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00176	0.00333	CcSEcCtD
Ziprasidone—CHRM4—nervous system—amyotrophic lateral sclerosis	0.00174	0.00744	CbGeAlD
Ziprasidone—HTR1D—brainstem—amyotrophic lateral sclerosis	0.00174	0.00742	CbGeAlD
Ziprasidone—HTR2C—brainstem—amyotrophic lateral sclerosis	0.00172	0.00734	CbGeAlD
Ziprasidone—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00322	CcSEcCtD
Ziprasidone—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00168	0.00318	CcSEcCtD
Ziprasidone—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00168	0.00318	CcSEcCtD
Ziprasidone—CHRM4—central nervous system—amyotrophic lateral sclerosis	0.00168	0.00716	CbGeAlD
Ziprasidone—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00168	0.00317	CcSEcCtD
Ziprasidone—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00168	0.00317	CcSEcCtD
Ziprasidone—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00167	0.00315	CcSEcCtD
Ziprasidone—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00166	0.00314	CcSEcCtD
Ziprasidone—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00165	0.00313	CcSEcCtD
Ziprasidone—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00165	0.00312	CcSEcCtD
Ziprasidone—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00165	0.00311	CcSEcCtD
Ziprasidone—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00164	0.0031	CcSEcCtD
Ziprasidone—SLC6A4—brainstem—amyotrophic lateral sclerosis	0.00163	0.00696	CbGeAlD
Ziprasidone—DRD3—nervous system—amyotrophic lateral sclerosis	0.00162	0.00692	CbGeAlD
Ziprasidone—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00296	CcSEcCtD
Ziprasidone—H1F0—medulla oblongata—amyotrophic lateral sclerosis	0.00156	0.00668	CbGeAlD
Ziprasidone—DRD3—central nervous system—amyotrophic lateral sclerosis	0.00156	0.00666	CbGeAlD
Ziprasidone—HTR6—nervous system—amyotrophic lateral sclerosis	0.00156	0.00666	CbGeAlD
Ziprasidone—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00156	0.00294	CcSEcCtD
Ziprasidone—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00152	0.00287	CcSEcCtD
Ziprasidone—HTR1E—brain—amyotrophic lateral sclerosis	0.00152	0.00649	CbGeAlD
Ziprasidone—DRD5—nervous system—amyotrophic lateral sclerosis	0.00152	0.00648	CbGeAlD
Ziprasidone—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00151	0.00286	CcSEcCtD
Ziprasidone—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00151	0.00285	CcSEcCtD
Ziprasidone—HTR2A—hindbrain—amyotrophic lateral sclerosis	0.00151	0.00643	CbGeAlD
Ziprasidone—Chills—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00284	CcSEcCtD
Ziprasidone—HTR6—central nervous system—amyotrophic lateral sclerosis	0.0015	0.00641	CbGeAlD
Ziprasidone—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00283	CcSEcCtD
Ziprasidone—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00148	0.0028	CcSEcCtD
Ziprasidone—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00277	CcSEcCtD
Ziprasidone—DRD5—central nervous system—amyotrophic lateral sclerosis	0.00146	0.00624	CbGeAlD
Ziprasidone—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00276	CcSEcCtD
Ziprasidone—HTR1A—brainstem—amyotrophic lateral sclerosis	0.00145	0.00618	CbGeAlD
Ziprasidone—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00144	0.00272	CcSEcCtD
Ziprasidone—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00141	0.00267	CcSEcCtD
Ziprasidone—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00265	CcSEcCtD
Ziprasidone—H1F0—spinal cord—amyotrophic lateral sclerosis	0.00139	0.00595	CbGeAlD
Ziprasidone—HTR7—brainstem—amyotrophic lateral sclerosis	0.00138	0.00591	CbGeAlD
Ziprasidone—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.00137	0.00586	CbGeAlD
Ziprasidone—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00258	CcSEcCtD
Ziprasidone—CHRM5—nervous system—amyotrophic lateral sclerosis	0.00136	0.00582	CbGeAlD
Ziprasidone—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00135	0.00255	CcSEcCtD
Ziprasidone—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00253	CcSEcCtD
Ziprasidone—ADRA1A—brainstem—amyotrophic lateral sclerosis	0.00133	0.0057	CbGeAlD
Ziprasidone—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00252	CcSEcCtD
Ziprasidone—CHRM4—brain—amyotrophic lateral sclerosis	0.00133	0.00569	CbGeAlD
Ziprasidone—CHRM5—central nervous system—amyotrophic lateral sclerosis	0.00131	0.0056	CbGeAlD
Ziprasidone—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00248	CcSEcCtD
Ziprasidone—DRD2—brainstem—amyotrophic lateral sclerosis	0.00131	0.00559	CbGeAlD
Ziprasidone—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00247	CcSEcCtD
Ziprasidone—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00247	CcSEcCtD
Ziprasidone—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00129	0.00244	CcSEcCtD
Ziprasidone—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00128	0.00242	CcSEcCtD
Ziprasidone—Cough—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00241	CcSEcCtD
Ziprasidone—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00238	CcSEcCtD
Ziprasidone—ADRA1B—nervous system—amyotrophic lateral sclerosis	0.00124	0.00531	CbGeAlD
Ziprasidone—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00235	CcSEcCtD
Ziprasidone—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00235	CcSEcCtD
Ziprasidone—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00235	CcSEcCtD
Ziprasidone—DRD3—brain—amyotrophic lateral sclerosis	0.00124	0.00529	CbGeAlD
Ziprasidone—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00234	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00233	CcSEcCtD
Ziprasidone—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00121	0.0023	CcSEcCtD
Ziprasidone—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00227	CcSEcCtD
Ziprasidone—HTR2C—medulla oblongata—amyotrophic lateral sclerosis	0.0012	0.00512	CbGeAlD
Ziprasidone—ADRA1B—central nervous system—amyotrophic lateral sclerosis	0.0012	0.00512	CbGeAlD
Ziprasidone—HTR6—brain—amyotrophic lateral sclerosis	0.00119	0.00509	CbGeAlD
Ziprasidone—Infection—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00224	CcSEcCtD
Ziprasidone—H1F0—nervous system—amyotrophic lateral sclerosis	0.00118	0.00502	CbGeAlD
Ziprasidone—Shock—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00221	CcSEcCtD
Ziprasidone—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00221	CcSEcCtD
Ziprasidone—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00117	0.0022	CcSEcCtD
Ziprasidone—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00116	0.0022	CcSEcCtD
Ziprasidone—DRD5—brain—amyotrophic lateral sclerosis	0.00116	0.00496	CbGeAlD
Ziprasidone—DRD1—nervous system—amyotrophic lateral sclerosis	0.00116	0.00495	CbGeAlD
Ziprasidone—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00219	CcSEcCtD
Ziprasidone—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00218	CcSEcCtD
Ziprasidone—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00214	CcSEcCtD
Ziprasidone—H1F0—central nervous system—amyotrophic lateral sclerosis	0.00113	0.00483	CbGeAlD
Ziprasidone—HTR3A—nervous system—amyotrophic lateral sclerosis	0.00112	0.00478	CbGeAlD
Ziprasidone—DRD1—central nervous system—amyotrophic lateral sclerosis	0.00112	0.00477	CbGeAlD
Ziprasidone—HTR1B—spinal cord—amyotrophic lateral sclerosis	0.00112	0.00476	CbGeAlD
Ziprasidone—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00111	0.0021	CcSEcCtD
Ziprasidone—H1F0—cerebellum—amyotrophic lateral sclerosis	0.00111	0.00472	CbGeAlD
Ziprasidone—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00205	CcSEcCtD
Ziprasidone—HTR3A—central nervous system—amyotrophic lateral sclerosis	0.00108	0.00461	CbGeAlD
Ziprasidone—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00204	CcSEcCtD
Ziprasidone—HTR2C—spinal cord—amyotrophic lateral sclerosis	0.00107	0.00457	CbGeAlD
Ziprasidone—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00202	CcSEcCtD
Ziprasidone—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00201	CcSEcCtD
Ziprasidone—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00106	0.002	CcSEcCtD
Ziprasidone—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00198	CcSEcCtD
Ziprasidone—CHRM5—brain—amyotrophic lateral sclerosis	0.00104	0.00445	CbGeAlD
Ziprasidone—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00196	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00194	CcSEcCtD
Ziprasidone—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00194	CcSEcCtD
Ziprasidone—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00192	CcSEcCtD
Ziprasidone—SLC6A4—spinal cord—amyotrophic lateral sclerosis	0.00101	0.00433	CbGeAlD
Ziprasidone—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000981	0.00185	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000974	0.00184	CcSEcCtD
Ziprasidone—HTR7—medulla oblongata—amyotrophic lateral sclerosis	0.000965	0.00412	CbGeAlD
Ziprasidone—ADRA1B—brain—amyotrophic lateral sclerosis	0.000951	0.00406	CbGeAlD
Ziprasidone—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000946	0.00179	CcSEcCtD
Ziprasidone—HTR2A—embryo—amyotrophic lateral sclerosis	0.000942	0.00402	CbGeAlD
Ziprasidone—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000941	0.00178	CcSEcCtD
Ziprasidone—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000941	0.00178	CcSEcCtD
Ziprasidone—HTR1B—nervous system—amyotrophic lateral sclerosis	0.00094	0.00401	CbGeAlD
Ziprasidone—CHRM2—nervous system—amyotrophic lateral sclerosis	0.000935	0.00399	CbGeAlD
Ziprasidone—HTR1D—nervous system—amyotrophic lateral sclerosis	0.00091	0.00389	CbGeAlD
Ziprasidone—HTR1B—central nervous system—amyotrophic lateral sclerosis	0.000905	0.00386	CbGeAlD
Ziprasidone—HTR2C—nervous system—amyotrophic lateral sclerosis	0.000901	0.00385	CbGeAlD
Ziprasidone—HTR1A—spinal cord—amyotrophic lateral sclerosis	0.0009	0.00384	CbGeAlD
Ziprasidone—CHRM2—central nervous system—amyotrophic lateral sclerosis	0.0009	0.00384	CbGeAlD
Ziprasidone—KCNH2—medulla oblongata—amyotrophic lateral sclerosis	0.000899	0.00384	CbGeAlD
Ziprasidone—H1F0—brain—amyotrophic lateral sclerosis	0.000898	0.00383	CbGeAlD
Ziprasidone—ADRA2C—medulla oblongata—amyotrophic lateral sclerosis	0.000887	0.00379	CbGeAlD
Ziprasidone—DRD1—brain—amyotrophic lateral sclerosis	0.000887	0.00379	CbGeAlD
Ziprasidone—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000877	0.00166	CcSEcCtD
Ziprasidone—HTR1D—central nervous system—amyotrophic lateral sclerosis	0.000876	0.00374	CbGeAlD
Ziprasidone—HTR2C—central nervous system—amyotrophic lateral sclerosis	0.000868	0.0037	CbGeAlD
Ziprasidone—HTR2A—brainstem—amyotrophic lateral sclerosis	0.000863	0.00368	CbGeAlD
Ziprasidone—HTR7—spinal cord—amyotrophic lateral sclerosis	0.00086	0.00367	CbGeAlD
Ziprasidone—HTR3A—brain—amyotrophic lateral sclerosis	0.000857	0.00366	CbGeAlD
Ziprasidone—SLC6A4—nervous system—amyotrophic lateral sclerosis	0.000854	0.00365	CbGeAlD
Ziprasidone—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000854	0.00161	CcSEcCtD
Ziprasidone—CHRM1—nervous system—amyotrophic lateral sclerosis	0.000851	0.00363	CbGeAlD
Ziprasidone—SLC6A4—central nervous system—amyotrophic lateral sclerosis	0.000823	0.00351	CbGeAlD
Ziprasidone—CHRM1—central nervous system—amyotrophic lateral sclerosis	0.00082	0.0035	CbGeAlD
Ziprasidone—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000815	0.00154	CcSEcCtD
Ziprasidone—KCNH2—spinal cord—amyotrophic lateral sclerosis	0.000802	0.00342	CbGeAlD
Ziprasidone—ADRA2C—spinal cord—amyotrophic lateral sclerosis	0.000791	0.00338	CbGeAlD
Ziprasidone—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000787	0.00149	CcSEcCtD
Ziprasidone—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.000786	0.00336	CbGeAlD
Ziprasidone—CHRM3—nervous system—amyotrophic lateral sclerosis	0.000762	0.00325	CbGeAlD
Ziprasidone—HTR1A—nervous system—amyotrophic lateral sclerosis	0.000759	0.00324	CbGeAlD
Ziprasidone—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000757	0.00143	CcSEcCtD
Ziprasidone—Rash—Riluzole—amyotrophic lateral sclerosis	0.000751	0.00142	CcSEcCtD
Ziprasidone—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00075	0.00142	CcSEcCtD
Ziprasidone—Headache—Riluzole—amyotrophic lateral sclerosis	0.000746	0.00141	CcSEcCtD
Ziprasidone—CHRM3—central nervous system—amyotrophic lateral sclerosis	0.000733	0.00313	CbGeAlD
Ziprasidone—HTR1A—central nervous system—amyotrophic lateral sclerosis	0.00073	0.00312	CbGeAlD
Ziprasidone—HTR7—nervous system—amyotrophic lateral sclerosis	0.000725	0.0031	CbGeAlD
Ziprasidone—HTR1B—brain—amyotrophic lateral sclerosis	0.000719	0.00307	CbGeAlD
Ziprasidone—CHRM2—brain—amyotrophic lateral sclerosis	0.000715	0.00305	CbGeAlD
Ziprasidone—HTR1A—cerebellum—amyotrophic lateral sclerosis	0.000714	0.00305	CbGeAlD
Ziprasidone—ADRA2A—medulla oblongata—amyotrophic lateral sclerosis	0.000708	0.00302	CbGeAlD
Ziprasidone—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000707	0.00134	CcSEcCtD
Ziprasidone—ADRA1A—nervous system—amyotrophic lateral sclerosis	0.000699	0.00299	CbGeAlD
Ziprasidone—HTR7—central nervous system—amyotrophic lateral sclerosis	0.000698	0.00298	CbGeAlD
Ziprasidone—HTR1D—brain—amyotrophic lateral sclerosis	0.000696	0.00297	CbGeAlD
Ziprasidone—HTR2C—brain—amyotrophic lateral sclerosis	0.000689	0.00294	CbGeAlD
Ziprasidone—DRD2—nervous system—amyotrophic lateral sclerosis	0.000686	0.00293	CbGeAlD
Ziprasidone—HTR7—cerebellum—amyotrophic lateral sclerosis	0.000682	0.00291	CbGeAlD
Ziprasidone—KCNH2—nervous system—amyotrophic lateral sclerosis	0.000675	0.00288	CbGeAlD
Ziprasidone—ADRA1A—central nervous system—amyotrophic lateral sclerosis	0.000673	0.00287	CbGeAlD
Ziprasidone—ADRA2C—nervous system—amyotrophic lateral sclerosis	0.000666	0.00284	CbGeAlD
Ziprasidone—DRD2—central nervous system—amyotrophic lateral sclerosis	0.00066	0.00282	CbGeAlD
Ziprasidone—ADRA1A—cerebellum—amyotrophic lateral sclerosis	0.000658	0.00281	CbGeAlD
Ziprasidone—SLC6A4—brain—amyotrophic lateral sclerosis	0.000653	0.00279	CbGeAlD
Ziprasidone—CHRM1—brain—amyotrophic lateral sclerosis	0.000651	0.00278	CbGeAlD
Ziprasidone—KCNH2—central nervous system—amyotrophic lateral sclerosis	0.00065	0.00278	CbGeAlD
Ziprasidone—DRD2—cerebellum—amyotrophic lateral sclerosis	0.000645	0.00275	CbGeAlD
Ziprasidone—ADRA2C—central nervous system—amyotrophic lateral sclerosis	0.000642	0.00274	CbGeAlD
Ziprasidone—KCNH2—cerebellum—amyotrophic lateral sclerosis	0.000636	0.00271	CbGeAlD
Ziprasidone—ADRA2A—spinal cord—amyotrophic lateral sclerosis	0.000631	0.00269	CbGeAlD
Ziprasidone—ADRA2C—cerebellum—amyotrophic lateral sclerosis	0.000627	0.00268	CbGeAlD
Ziprasidone—HTR2A—medulla oblongata—amyotrophic lateral sclerosis	0.000602	0.00257	CbGeAlD
Ziprasidone—CHRM3—brain—amyotrophic lateral sclerosis	0.000582	0.00249	CbGeAlD
Ziprasidone—HTR1A—brain—amyotrophic lateral sclerosis	0.00058	0.00248	CbGeAlD
Ziprasidone—HTR7—brain—amyotrophic lateral sclerosis	0.000554	0.00237	CbGeAlD
Ziprasidone—HRH1—nervous system—amyotrophic lateral sclerosis	0.000541	0.00231	CbGeAlD
Ziprasidone—HTR2A—spinal cord—amyotrophic lateral sclerosis	0.000537	0.00229	CbGeAlD
Ziprasidone—ADRA1A—brain—amyotrophic lateral sclerosis	0.000535	0.00228	CbGeAlD
Ziprasidone—ADRA2A—nervous system—amyotrophic lateral sclerosis	0.000532	0.00227	CbGeAlD
Ziprasidone—DRD2—brain—amyotrophic lateral sclerosis	0.000524	0.00224	CbGeAlD
Ziprasidone—HRH1—central nervous system—amyotrophic lateral sclerosis	0.000521	0.00223	CbGeAlD
Ziprasidone—KCNH2—brain—amyotrophic lateral sclerosis	0.000516	0.0022	CbGeAlD
Ziprasidone—ADRA2A—central nervous system—amyotrophic lateral sclerosis	0.000512	0.00219	CbGeAlD
Ziprasidone—ADRA2C—brain—amyotrophic lateral sclerosis	0.000509	0.00217	CbGeAlD
Ziprasidone—ADRA2A—cerebellum—amyotrophic lateral sclerosis	0.0005	0.00214	CbGeAlD
Ziprasidone—HTR2A—nervous system—amyotrophic lateral sclerosis	0.000452	0.00193	CbGeAlD
Ziprasidone—HTR2A—central nervous system—amyotrophic lateral sclerosis	0.000435	0.00186	CbGeAlD
Ziprasidone—HTR2A—cerebellum—amyotrophic lateral sclerosis	0.000425	0.00182	CbGeAlD
Ziprasidone—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000419	0.00179	CbGeAlD
Ziprasidone—HRH1—brain—amyotrophic lateral sclerosis	0.000414	0.00177	CbGeAlD
Ziprasidone—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000412	0.00176	CbGeAlD
Ziprasidone—ADRA2A—brain—amyotrophic lateral sclerosis	0.000406	0.00174	CbGeAlD
Ziprasidone—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000403	0.00172	CbGeAlD
Ziprasidone—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000397	0.00169	CbGeAlD
Ziprasidone—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000388	0.00165	CbGeAlD
Ziprasidone—HTR2A—brain—amyotrophic lateral sclerosis	0.000346	0.00148	CbGeAlD
Ziprasidone—CYP2D6—brain—amyotrophic lateral sclerosis	0.000315	0.00134	CbGeAlD
Ziprasidone—DRD5—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.84e-05	0.000217	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.83e-05	0.000216	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.83e-05	0.000216	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.82e-05	0.000215	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.82e-05	0.000215	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.81e-05	0.000214	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.8e-05	0.000212	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.79e-05	0.000212	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.79e-05	0.000212	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.79e-05	0.000211	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.77e-05	0.000209	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.77e-05	0.000209	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.76e-05	0.000208	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.74e-05	0.000205	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.74e-05	0.000205	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.74e-05	0.000205	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.73e-05	0.000204	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.72e-05	0.000204	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.72e-05	0.000203	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.72e-05	0.000203	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.71e-05	0.000202	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.71e-05	0.000202	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.7e-05	0.000201	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.7e-05	0.000201	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.7e-05	0.000201	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.69e-05	0.000199	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.68e-05	0.000199	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.67e-05	0.000197	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.66e-05	0.000197	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.66e-05	0.000196	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.65e-05	0.000195	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	1.65e-05	0.000195	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.65e-05	0.000195	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.64e-05	0.000194	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.64e-05	0.000194	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.64e-05	0.000194	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.63e-05	0.000193	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.63e-05	0.000192	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.62e-05	0.000192	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.62e-05	0.000192	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.62e-05	0.000191	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.6e-05	0.000189	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.6e-05	0.000189	CbGpPWpGaD
Ziprasidone—ADRA2A—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.59e-05	0.000188	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.59e-05	0.000188	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.59e-05	0.000187	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.58e-05	0.000187	CbGpPWpGaD
Ziprasidone—ADRA2B—Hemostasis—TP53—amyotrophic lateral sclerosis	1.58e-05	0.000187	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.58e-05	0.000187	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.58e-05	0.000186	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.57e-05	0.000185	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.56e-05	0.000185	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.55e-05	0.000183	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.54e-05	0.000182	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.54e-05	0.000181	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	1.52e-05	0.00018	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—APOE—amyotrophic lateral sclerosis	1.51e-05	0.000179	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.51e-05	0.000178	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.51e-05	0.000178	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.49e-05	0.000176	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.48e-05	0.000175	CbGpPWpGaD
Ziprasidone—ADRA2C—Hemostasis—TP53—amyotrophic lateral sclerosis	1.48e-05	0.000175	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.48e-05	0.000174	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.47e-05	0.000174	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—APOE—amyotrophic lateral sclerosis	1.47e-05	0.000174	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.46e-05	0.000172	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.45e-05	0.000171	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.45e-05	0.000171	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.44e-05	0.00017	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.42e-05	0.000168	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.42e-05	0.000167	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.42e-05	0.000167	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.42e-05	0.000167	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.41e-05	0.000167	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.41e-05	0.000167	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.41e-05	0.000167	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.41e-05	0.000166	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.41e-05	0.000166	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.39e-05	0.000164	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.39e-05	0.000164	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.38e-05	0.000163	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.36e-05	0.000161	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.36e-05	0.00016	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.36e-05	0.00016	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.36e-05	0.00016	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.36e-05	0.00016	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.34e-05	0.000158	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.34e-05	0.000158	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.33e-05	0.000157	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.33e-05	0.000157	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.33e-05	0.000157	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.33e-05	0.000157	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.32e-05	0.000156	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.32e-05	0.000156	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.32e-05	0.000155	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.31e-05	0.000155	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.31e-05	0.000154	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—APOE—amyotrophic lateral sclerosis	1.3e-05	0.000154	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.3e-05	0.000153	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.29e-05	0.000152	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.28e-05	0.000151	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.27e-05	0.00015	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.26e-05	0.000149	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	1.25e-05	0.000148	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.23e-05	0.000145	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.22e-05	0.000144	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.21e-05	0.000143	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.21e-05	0.000143	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.2e-05	0.000142	CbGpPWpGaD
Ziprasidone—ADRA2A—Hemostasis—TP53—amyotrophic lateral sclerosis	1.2e-05	0.000142	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.2e-05	0.000142	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.2e-05	0.000141	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—APOE—amyotrophic lateral sclerosis	1.19e-05	0.000141	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.18e-05	0.000139	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.18e-05	0.000139	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.17e-05	0.000138	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.17e-05	0.000138	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.16e-05	0.000137	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.15e-05	0.000136	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.11e-05	0.000132	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.1e-05	0.00013	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.09e-05	0.000129	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	1.09e-05	0.000129	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.09e-05	0.000129	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.09e-05	0.000129	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.09e-05	0.000129	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.09e-05	0.000128	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.09e-05	0.000128	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.08e-05	0.000128	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.08e-05	0.000127	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.07e-05	0.000127	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.07e-05	0.000127	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.06e-05	0.000125	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.05e-05	0.000124	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.04e-05	0.000123	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.04e-05	0.000123	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.04e-05	0.000122	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.03e-05	0.000122	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.03e-05	0.000122	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.03e-05	0.000122	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.03e-05	0.000122	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.02e-05	0.000121	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.02e-05	0.000121	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.02e-05	0.00012	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.01e-05	0.00012	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.01e-05	0.000119	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1e-05	0.000118	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	9.99e-06	0.000118	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	9.98e-06	0.000118	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.86e-06	0.000116	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.86e-06	0.000116	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.73e-06	0.000115	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.45e-06	0.000112	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.39e-06	0.000111	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.32e-06	0.00011	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.27e-06	0.000109	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.26e-06	0.000109	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.25e-06	0.000109	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	9.21e-06	0.000109	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.19e-06	0.000109	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	9.07e-06	0.000107	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9.06e-06	0.000107	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	9.05e-06	0.000107	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	9.02e-06	0.000107	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9e-06	0.000106	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.99e-06	0.000106	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.91e-06	0.000105	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.9e-06	0.000105	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.88e-06	0.000105	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.88e-06	0.000105	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.85e-06	0.000105	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.76e-06	0.000103	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.73e-06	0.000103	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.72e-06	0.000103	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.37e-06	9.88e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.36e-06	9.88e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.25e-06	9.74e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.18e-06	9.66e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.08e-06	9.54e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.04e-06	9.49e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.01e-06	9.46e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.97e-06	9.41e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7.91e-06	9.34e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.86e-06	9.29e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.82e-06	9.23e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	7.78e-06	9.19e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.69e-06	9.09e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7.63e-06	9.02e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7.59e-06	8.97e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.5e-06	8.85e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7.39e-06	8.72e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7.27e-06	8.59e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.1e-06	8.39e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.09e-06	8.38e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—TP53—amyotrophic lateral sclerosis	7e-06	8.26e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.99e-06	8.25e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.98e-06	8.24e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.96e-06	8.22e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.94e-06	8.2e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.94e-06	8.2e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.92e-06	8.17e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.85e-06	8.1e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.85e-06	8.09e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.83e-06	8.07e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.82e-06	8.05e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.8e-06	8.03e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.73e-06	7.94e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.7e-06	7.92e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.69e-06	7.9e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.63e-06	7.83e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.6e-06	7.8e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.59e-06	7.79e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	6.59e-06	7.78e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.58e-06	7.77e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.56e-06	7.75e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.54e-06	7.72e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.53e-06	7.71e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.47e-06	7.65e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.46e-06	7.63e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.35e-06	7.5e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.32e-06	7.47e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.18e-06	7.3e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.02e-06	7.11e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.02e-06	7.11e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6e-06	7.09e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.94e-06	7.02e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.92e-06	6.99e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.91e-06	6.98e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.89e-06	6.96e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.87e-06	6.93e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.81e-06	6.87e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.8e-06	6.85e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.39e-06	6.36e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.36e-06	6.34e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.33e-06	6.3e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.18e-06	6.12e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.15e-06	6.09e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	5.09e-06	6.01e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.01e-06	5.92e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.93e-06	5.83e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.55e-06	5.37e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.51e-06	5.33e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.47e-06	5.28e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.46e-06	5.27e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.45e-06	5.26e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.44e-06	5.24e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.39e-06	5.19e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.38e-06	5.17e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.07e-06	4.81e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.48e-06	4.12e-05	CbGpPWpGaD
